Clinical Trial Update: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating CDX-0159 in patients with chronic spontaneous urticaria. The study status is listed as COMPLE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• CDX-0159

Snippet

Sponsor: Celldex Therapeutics | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED